Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD.

Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

2.

DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.

Leaf RK, Stroopinsky D, Pyzer AR, Kruisbeek AM, van Wetering S, Washington A, Ephraim A, Cole L, Morin A, Jain S, Nahas MR, Apel A, Arnason J, Hamdan A, Rosenblatt J, Avigan D.

J Immunother. 2017 Nov/Dec;40(9):315-322. doi: 10.1097/CJI.0000000000000185.

PMID:
28961609
3.

In Vivo Depletion of T Lymphocytes.

Laky K, Kruisbeek AM.

Curr Protoc Immunol. 2016 Apr 1;113:4.1.1-9. doi: 10.1002/0471142735.im0401s113.

PMID:
27038463
4.

Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy.

van den Ancker W, Wijnands PG, Ruben JM, Westers TM, Punt B, Bachas C, Ravenshorst N, van Wetering S, Kruisbeek AM, Bontkes HJ, Ossenkoppele GJ, van de Loosdrecht AA, de Gruijl TD.

Immunotherapy. 2013 Nov;5(11):1183-90. doi: 10.2217/imt.13.125.

PMID:
24188673
5.

Phage display generation of a novel human anti-CD1A monoclonal antibody with potent cytolytic activity.

Bechan GI, Lee DW, Zajonc DM, Heckel D, Xian R, Throsby M, van Meijer M, Germeraad WT, Kruisbeek AM, Egeler RM, Arceci RJ.

Br J Haematol. 2012 Nov;159(3):299-310. doi: 10.1111/bjh.12033. Epub 2012 Aug 30.

PMID:
22934889
6.

Exposure of CD34+ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy.

van de Ven R, Reurs AW, Wijnands PGJTB, van Wetering S, Kruisbeek AM, Hooijberg E, Scheffer GL, Scheper RJ, de Gruijl TD.

Cancer Immunol Immunother. 2012 Feb;61(2):181-191. doi: 10.1007/s00262-011-1039-x. Epub 2011 Aug 27.

PMID:
21874304
7.

Proliferative assays for T cell function.

Kruisbeek AM, Shevach E, Thornton AM.

Curr Protoc Immunol. 2004 May;Chapter 3:Unit 3.12. doi: 10.1002/0471142735.im0312s60. Review.

PMID:
18432927
8.

In vivo depletion of CD4- and CD8-specific T cells.

Kruisbeek AM.

Curr Protoc Immunol. 2001 May;Chapter 4:Unit 4.1. doi: 10.1002/0471142735.im0401s01.

PMID:
18432792
9.

Production of mouse T cell hybridomas.

Kruisbeek AM.

Curr Protoc Immunol. 2001 May;Chapter 3:Unit 3.14. doi: 10.1002/0471142735.im0314s24.

PMID:
18432780
10.

Isolation of mouse mononuclear cells.

Kruisbeek AM.

Curr Protoc Immunol. 2001 May;Chapter 3:Unit 3.1. doi: 10.1002/0471142735.im0301s39.

PMID:
18432779
11.

Commonly used mouse strains.

Kruisbeek AM.

Curr Protoc Immunol. 2001 May;Appendix 1:Appendix 1C. doi: 10.1002/0471142735.ima01cs17.

PMID:
18432639
12.

Importance of the CD3gamma ectodomain terminal beta-strand and membrane proximal stalk in thymic development and receptor assembly.

Touma M, Sun ZY, Clayton LK, Marissen WE, Kruisbeek AM, Wagner G, Reinherz EL.

J Immunol. 2007 Mar 15;178(6):3668-79.

13.

Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB.

J Immunol. 2006 May 1;176(9):5213-22.

14.

Affinity ranking of antibodies using flow cytometry: application in antibody phage display-based target discovery.

Geuijen CA, Clijsters-van der Horst M, Cox F, Rood PM, Throsby M, Jongeneelen MA, Backus HH, van Deventer E, Kruisbeek AM, Goudsmit J, de Kruif J.

J Immunol Methods. 2005 Jul;302(1-2):68-77.

PMID:
15992810
15.

A proteomic approach to tumour target identification using phage display, affinity purification and mass spectrometry.

Geuijen CA, Bijl N, Smit RC, Cox F, Throsby M, Visser TJ, Jongeneelen MA, Bakker AB, Kruisbeek AM, Goudsmit J, de Kruif J.

Eur J Cancer. 2005 Jan;41(1):178-87.

PMID:
15618003
16.

C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia.

Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA, Jongeneelen MA, Visser TJ, Bijl N, Geuijen CA, Marissen WE, Radosevic K, Throsby M, Schuurhuis GJ, Ossenkoppele GJ, de Kruif J, Goudsmit J, Kruisbeek AM.

Cancer Res. 2004 Nov 15;64(22):8443-50.

17.
18.

Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers.

Bischof F, Hofmann M, Schumacher TN, Vyth-Dreese FA, Weissert R, Schild H, Kruisbeek AM, Melms A.

J Immunol. 2004 Mar 1;172(5):2878-84.

19.

The impact of self-tolerance on the polyclonal CD8+ T cell repertoire.

Kessels HW, de Visser KE, Tirion FH, Coccoris M, Kruisbeek AM, Schumacher TN.

J Immunol. 2004 Feb 15;172(4):2324-31.

20.

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP.

J Exp Med. 2003 Aug 18;198(4):569-80.

21.

In Vitro Assays for Mouse Lymphocyte Function.

Kruisbeek AM.

Curr Protoc Immunol. 2003 Jun;55(1):1. doi: 10.1002/0471142735.im0300s55. No abstract available.

PMID:
29921115
22.

CD8+ T cell tolerance and cancer immunotherapy.

De Visser KE, Schumacher TN, Kruisbeek AM.

J Immunother. 2003 Jan-Feb;26(1):1-11. Review.

PMID:
12514424
23.

Contributions of the T cell receptor-associated CD3gamma-ITAM to thymocyte selection.

Haks MC, Pépin E, van den Brakel JH, Smeele SA, Belkowski SM, Kessels HW, Krimpenfort P, Kruisbeek AM.

J Exp Med. 2002 Jul 1;196(1):1-13.

24.

Peptide-induced negative selection of thymocytes activates transcription of an NF-kappa B inhibitor.

Fiorini E, Schmitz I, Marissen WE, Osborn SL, Touma M, Sasada T, Reche PA, Tibaldi EV, Hussey RE, Kruisbeek AM, Reinherz EL, Clayton LK.

Mol Cell. 2002 Mar;9(3):637-48.

25.

Circumventing T-cell tolerance to tumour antigens.

Kessels HW, de Visser KE, Kruisbeek AM, Schumacher TN.

Biologicals. 2001 Sep-Dec;29(3-4):277-83.

PMID:
11851328
26.

Early growth response transcription factors are required for development of CD4(-)CD8(-) thymocytes to the CD4(+)CD8(+) stage.

Carleton M, Haks MC, Smeele SA, Jones A, Belkowski SM, Berger MA, Linsley P, Kruisbeek AM, Wiest DL.

J Immunol. 2002 Feb 15;168(4):1649-58.

27.

Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?

Cordaro TA, de Visser KE, Tirion FH, Schumacher TN, Kruisbeek AM.

J Immunol. 2002 Jan 15;168(2):651-60.

28.

Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes.

Bischof F, Wienhold W, Wirblich C, Malcherek G, Zevering O, Kruisbeek AM, Melms A.

Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12168-73. Epub 2001 Oct 2.

29.

Low-avidity self-specific T cells display a pronounced expansion defect that can be overcome by altered peptide ligands.

de Visser KE, Cordaro TA, Kessels HW, Tirion FH, Schumacher TN, Kruisbeek AM.

J Immunol. 2001 Oct 1;167(7):3818-28.

30.

A redundant role of the CD3 gamma-immunoreceptor tyrosine-based activation motif in mature T cell function.

Haks MC, Cordaro TA, van den Brakel JH, Haanen JB, de Vries EF, Borst J, Krimpenfort P, Kruisbeek AM.

J Immunol. 2001 Feb 15;166(4):2576-88.

31.

Branching out to gain control: how the pre-TCR is linked to multiple functions.

Kruisbeek AM, Haks MC, Carleton M, Michie AM, Zúñiga-Pflücker JC, Wiest DL.

Immunol Today. 2000 Dec;21(12):637-44. Review.

PMID:
11114425
32.

In situ detection of virus- and tumor-specific T-cell immunity.

Haanen JB, van Oijen MG, Tirion F, Oomen LC, Kruisbeek AM, Vyth-Dreese FA, Schumacher TN.

Nat Med. 2000 Sep;6(9):1056-60. No abstract available.

PMID:
10973329
33.

Tracing and characterization of the low-avidity self-specific T cell repertoire.

de Visser KE, Cordaro TA, Kioussis D, Haanen JB, Schumacher TN, Kruisbeek AM.

Eur J Immunol. 2000 May;30(5):1458-68.

34.

Tumor size at the time of adoptive transfer determines whether tumor rejection occurs.

Cordaro TA, de Visser KE, Tirion FH, Graus YM, Haanen JB, Kioussis D, Kruisbeek AM.

Eur J Immunol. 2000 May;30(5):1297-307.

35.

Selective expansion of cross-reactive CD8(+) memory T cells by viral variants.

Haanen JB, Wolkers MC, Kruisbeek AM, Schumacher TN.

J Exp Med. 1999 Nov 1;190(9):1319-28.

36.

Pre-TCR signaling and inactivation of p53 induces crucial cell survival pathways in pre-T cells.

Haks MC, Krimpenfort P, van den Brakel JH, Kruisbeek AM.

Immunity. 1999 Jul;11(1):91-101.

37.

Systemic T cell expansion during localized viral infection.

Haanen JB, Toebes M, Cordaro TA, Wolkers MC, Kruisbeek AM, Schumacher TN.

Eur J Immunol. 1999 Apr;29(4):1168-74.

38.

Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR.

Haks MC, Oosterwegel MA, Blom B, Spits HM, Kruisbeek AM.

Semin Immunol. 1999 Feb;11(1):23-37. Review.

PMID:
9950750
39.

Introduction: regulation of T cell development by the thymic microenvironment.

Kruisbeek AM.

Semin Immunol. 1999 Feb;11(1):1-2. No abstract available.

PMID:
9950747
40.

Costimulatory signals are required for induction of transcription factor Nur77 during negative selection of CD4(+)CD8(+) thymocytes.

Amsen D, Revilla Calvo C, Osborne BA, Kruisbeek AM.

Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):622-7.

41.

Thymocyte selection: not by TCR alone.

Amsen D, Kruisbeek AM.

Immunol Rev. 1998 Oct;165:209-29. Review.

PMID:
9850863
42.

Functional analysis of Ran/TC4 as a protein regulating T-cell costimulation.

Nieland JD, Haks MC, Kremers BL, Leupers TJ, Bakker AQ, Offringa R, Kruisbeek AM.

Cancer Gene Ther. 1998 Sep-Oct;5(5):259-73.

PMID:
9824045
43.

The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2.

Gravestein LA, Amsen D, Boes M, Calvo CR, Kruisbeek AM, Borst J.

Eur J Immunol. 1998 Jul;28(7):2208-16.

44.
45.

The CD3gamma chain is essential for development of both the TCRalphabeta and TCRgammadelta lineages.

Haks MC, Krimpenfort P, Borst J, Kruisbeek AM.

EMBO J. 1998 Apr 1;17(7):1871-82.

46.

CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response.

Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM.

J Immunother. 1998 May;21(3):225-36.

PMID:
9610915
48.
50.

CD28-B7 interactions function to co-stimulate clonal deletion of double-positive thymocytes.

Amsen D, Kruisbeek AM.

Int Immunol. 1996 Dec;8(12):1927-36.

PMID:
8982777

Supplemental Content

Loading ...
Support Center